Interim Results From Fight-203, A Phase 2, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Pemigatinib (Incb054828) In Patients With Myeloid/Lymphoid Neoplasms With Rearrangement Of Fibroblast Growth Factor Receptor 1 (Fgfr1)
BLOOD（2018）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要